Guided Therapeutics (GTHP) Liabilities and Shareholders Equity (2010 - 2026)

Guided Therapeutics has disclosed Liabilities and Shareholders Equity across 17 years of filings, most recently posting $1.2 million for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 27.13% year-over-year to $1.2 million; the TTM figure through Jun 2026 stood at $5.0 million (up 10.85% YoY), while the FY2025 annual figure was $1.3 million, down 3.92% from the prior year.
• Liabilities and Shareholders Equity came in at $1.2 million for Q2 2026 at Guided Therapeutics, down from $1.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $3.9 million in Q3 2022 to a low of $903000.0 in Q3 2025.
• Average Liabilities and Shareholders Equity over 5 years is $1.8 million, with a median of $1.5 million recorded in 2022.
• Year-over-year, Liabilities and Shareholders Equity jumped 121.96% in 2022 and plunged 51.51% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $3.4 million in 2022, then tumbled by 50.42% to $1.7 million in 2023, then fell by 17.44% to $1.4 million in 2024, then declined by 3.92% to $1.3 million in 2025, then slipped by 9.74% to $1.2 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $1.2 million in Q2 2026, $1.6 million in Q1 2026, and $1.3 million in Q4 2025.